#pharma

The discussion centered on a practical point: reliable agents depend on data quality, evaluation, recovery, and observability more than workflow diagrams.

Novo Nordisk raised its full-year 2026 guidance after Q1 sales hit $15.2 billion (+32% constant currency), driven by the oral Wegovy pill which now commands 65% of new GLP-1 prescriptions in the United States.

Organon $OGN rose about 31% before the bell after Sun Pharma $SUNPHARMA agreed to pay $14 a share in cash, valuing the target at $11.75B including debt. Sun said the combination would create a $12.4B-revenue pharma group with a larger women’s-health and biosimilars footprint.